Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prevention of bladder dysfunction in acute spinal cord injury
2012-002211-25Phase 4Completed
- Sponsor
- Oslo University Hospital
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of botulinum toxin type A in neurogenic bladder and spinal cord injury (SCI), sponsored by Oslo University Hospital. Primary endpoint: Development of detrusor overactivity. Started Oct 2012; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
neurogenic bladderspinal cord injury (SCI)
Beyond the preview
Go deeper on 2012-002211-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002211-25.